Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Donald Zuhn — On Monday, SparkIP launched a beta version of its new online intellectual property exchange, SparkIP.com. The site, which SparkIP describes as "an advanced research and commerce platform for the scientific community," is designed to connect scientists, inventors, licensors, licensees, corporations, universities, government labs, and patent attorneys with one another;…
-
By Kevin E. Noonan — Reliable sources inform Patent Docs that the House of Representatives, having finished its summer portion of mischief by passing H.R. 1908 "reforming" U.S. patent law into unrecognizability, is set to turn its attention to the bill, introduced by Congressman Becerra (31st Dist., Cal.) (at right), that would ban…
-
By Kevin E. Noonan — As reported earlier by a variety of news sources, the J. Craig Venter Institute published today the sequence of a complete diploid human genomic complement, fitting that of the eponymous Dr. Venter (below), on the Public Library of Science (PLoS) website. This sequence differs in several ways from…
-
By Kevin E. Noonan — There have been two distinct stages in the developing world’s reaction to the patent-related provisions of the General Agreement on Tariffs and Trade (GATT) and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that established the World Trade Organization (WTO). The first is illustrated by Article…
-
By Donald Zuhn — Last Friday, The San Francisco Chronicle reported on new challenges facing the biotech industry. In an article by Bernadette Tansey entitled "As biotech patents run out, innovation and competition may thrive," the Chronicle addressed the expiration of key biotech patents, increased competition being applied by generic manufacturers, and new…
-
By Kevin E. Noonan — There may be some good news with regard to the safety of generic drugs obtained from China. Despite recent evidence that the U.S. Food and Drug Administration has been woefully deficient in inspecting generic drug manufacturers overseas (see "The Effect of Foreign Generics on the U.S. Drug Supply…
-
By Kevin E. Noonan — The crisis in global drug pricing that has arisen since the institution of the World Trade Organization (WTO), and in particular with regard to the Doha Declaration (see "The Law of Unintended Consequences Arises in Applying TRIPS to Patented Drug Protection in Developing Countries"), is well-recognized. While the…
-
By Kevin E. Noonan — The measure of sanity displayed by Abbott and Brasil last week, when the parties agreed to a pricing scheme that avoided "breaking" Abbott’s patent on its anti-AIDS drug Kaletra® (see "Brasil Prevails in Dispute with Abbott over AIDS Drug Pricing") has not translated to the Eastern hemisphere. Thailand,…
-
By Kevin E. Noonan — A measure of sanity returned last week, when the Brasilian Health Ministry and Abbott Laboratories announced an agreement on a pricing regime for Abbott’s anti-AIDS drug, Kaletra®. Under this agreement, Brasil will not "break" Abbott’s patent by permitting sale or importation of a generic version of the drug.…
-
By Kevin E. Noonan — Although it is well past time to stop the hypocrisy over stem cell patents (see Part I and Part II of this series), the forces aligned against the Thomson human embryonic stem cell patents refuse to do so. This was made evident again this week, when additional voices,…
Patent Docs 